GlassScriptPhysician profile
Ellen Skeadas Grody
NPI 1275219255
$1,927.25
in general payments reported to CMS, 2019-2025
30 companies · $1,632 in 2025
The $1,632 reported for 2025 was more than what 90% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $67.67 · 2024: $228 · 2025: $1,632.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,927.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,927.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $252.02 | 2025 | |
| Genentech USA, INC. | $240.92 | 2023-2024 | Vabysmo |
| Otsuka America Pharmaceutical, INC. | $199.68 | 2025 | Rexulti |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $153.20 | 2025 | Xifaxan |
| Novo Nordisk INC | $149.13 | 2025 | Ozempic, Rybelsus, Wegovy |
| Dexcom, INC. | $84.91 | 2024-2025 | Dexcom G6 Transmitter |
| Lundbeck LLC | $80.92 | 2025 | Vyepti, Rexulti |
| Axsome Therapeutics, INC. | $71.26 | 2025 | Auvelity |
| Lilly USA, LLC | $69.17 | 2025 | Mounjaro, Zepbound, Jardiance |
| Antares Pharma, INC. | $63.52 | 2025 | Xyosted |
| Novartis Pharmaceuticals Corporation | $63.46 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $54.67 | 2025 | Breztri, Airsupra |
| Regeneron Healthcare Solutions, INC. | $36.72 | 2024 | Eylea |
| Merck Sharp & Dohme LLC | $35.02 | 2025 | Verquvo |
| Vanda Pharmaceuticals INC. | $34.37 | 2025 | Fanapt |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $33.09 | 2025 | Repatha, Otezla |
| Insulet Corporation | $32.74 | 2025 | Omnipod |
| Teva Pharmaceuticals USA, INC. | $30.11 | 2025 | Austedo Xr |
| Exact Sciences Corporation | $29.26 | 2025 | Cologuard Collection Kit |
| Eisai INC. | $25.27 | 2025 | |
| Radius Health, INC. | $24.17 | 2025 | |
| Glaxosmithkline, LLC. | $23.82 | 2025 | Trelegy Ellipta |
| Cvrx, INC. | $21.95 | 2025 | Barostim Neo System |
| Janssen Pharmaceuticals, INC | $19.24 | 2025 | Spravato |
| Ardelyx, INC. | $18.79 | 2025 | Ibsrela |
| Idorsia Pharmaceuticals US INC | $17.52 | 2025 | Quviviq |
| Inspire Medical Systems, INC. | $16.45 | 2025 | Inspire |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $16.12 | 2025 | Caplyta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.44 | 2025 | Jardiance |
| Phathom Pharmaceuticals, INC. | $14.31 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ellen Skeadas Grody listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.